LUNDBECK PHARMA A/S: Financial statements 2015
CVR: 56750215
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
LUNDBECK PHARMA A/S (CVR 56750215) has filed annual accounts for 2015. In 2015, the company reported revenue of DKK 27,047,000 and a net result of DKK -129,000 compared with DKK 184,000 the year before. That is a decrease of 2.4% compared with the year before. The profit margin was -0.5%. Equity in the 2015 report amounted to DKK 2,969,000. The solvency ratio was 11.6%.
- Revenue
- DKK 27,047,000
- Gross Profit
- DKK 4,903,000
- Profit/Loss
- DKK -129,000
- Equity
- DKK 2,969,000
- Total Assets
- DKK 25,696,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | 27 mio. | 4.9 mio. | -129 t. | 3 mio. | - |
| 2014 | 27.7 mio. | 3.3 mio. | 184 t. | 3.1 mio. | - |
| 2013 | 33 mio. | 24.3 mio. | -89 t. | 3 mio. | - |
| 2012 | 43.8 mio. | 28.4 mio. | 691 t. | 3 mio. | - |
Official annual report
How creditworthy is LUNDBECK PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of December 1, 2015, Christoffer Dahl has joined the board of directors of LUNDBECK PHARMA A/S.
As of December 1, 2015, Thomas Bo Bjørn Klee has left the board of directors of LUNDBECK PHARMA A/S.
LUNDBECK PHARMA A/S has published its annual report for 2014. Revenue came to DKK 27,725,000, and the net result was DKK 184,000.
About LUNDBECK PHARMA A/S
LUNDBECK PHARMA A/S is a Danish company of the type Aktieselskab based in Valby, founded in 1958. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named HANS LUNDBECK A/S. The management consists of Søren Klein-Kristensen. The board consists of Michala Fischer-Hansen (chair), Søren Klein-Kristensen and Thomas Bo Bjørn Klee. The company is owned by H. LUNDBECK A/S. The company has 18 employees (2026). In 2025, the company reported revenue of DKK 18,887,000 and a net result of DKK 2,291,000 compared with DKK 1,820,000 the year before. Equity in the 2025 report amounted to DKK 3,378,000.